OR21-05 Low-dose Infigratinib, An Oral Selective Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, Demonstrates Activity In Murine Models Of Achondroplasia And Hypochondroplasia

Disclosure: E. Muslimova: Employee; Self; QED Therapeutics. Stock Owner; Self; QED Therapeutics. B. Demuynck: None. L. Loisay: None. M. Paull: Employee; Self; QED Therapeutics. Stock Owner; Self; QED Therapeutics. L. Legeai-Mallet: None. Background: FGFR3 is a negative regulator of bone growth and g...

Descripción completa

Detalles Bibliográficos
Autores principales: Muslimova, Elena, Demuynck, Benoit, Loisay, Léa, Paull, Morgan, Legeai-Mallet, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554941/
http://dx.doi.org/10.1210/jendso/bvad114.1523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554941/
http://dx.doi.org/10.1210/jendso/bvad114.1523

Ejemplares similares